ArticleCentral European journal of urology2026
A novel approach to Peyronie's disease: Intralesional injection of lyophilized platelet-derived growth factors.
Article in Central European journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Platelets store numerous growth factors that are released upon activation at sites of tissue injury. These factors support the wound healing process by enhancing chemotaxis, angiogenesis, cellular proliferation, extracellular matrix synthesis, and tissue remodeling.The aim of the study was to evaluate the therapeutic effect of intralesional lyophilized platelet-derived growth factors (PDGF) in men with Peyronie's disease (PD). Material and methods: This prospective study included 42 patients diagnosed with PD between June 2022 and October 2023; four were lost to follow-up. After providing informed consent, all participants underwent clinical evaluation, including medical history, physical examination, Sexual Health Inventory for Men (SHIM), Erection Hardness Score (EHS), Peyronie's Disease Questionnaire (PDQ), intracavernosal injection test, and penile duplex ultrasonography. Patients received six biweekly intralesional injections of lyophilized PDGF (one vial every two weeks over 12 weeks). Results: A significant reduction in penile curvature was observed, with the mean angle decreasing from 34.62 ±16.37° to 11.40 ±8.84° (mean reduction of 23.22°). Plaque size was also significantly reduced, from a mean of 2.70 ±0.87 cm to 1.43 ±0.44 cm. PDQ scores improved in all domains: Domain 1 by 9.18 points, Domain 2 by 14.74 points, and Domain 3 by 8.3 points. Additionally, erectile function improved, with no patients reporting an EHS grade of E1 or E2 after treatment. Conclusions: Intralesional injection of lyophilized PDGF appears to be a promising non-surgical option for improving curvature, plaque size, and sexual function in patients with Peyronie's disease. Further studies are recommended to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.